Press Room

2021 CPhI North America

Start
Tuesday, August 10, 2021 - 00:00
End
Thursday, August 12, 2021 - 00:00
Location: Philadelphia, USA
Booth Number: 1409
2021 CPhI North America | Hovione

 

 

We are ready to safely return to CPhI North America next August 10-12 in Philadelphia and we look forward to seeing you.



If you would like to reconnect face-to-face with Hovione’s team at our booth or if you still prefer to meet us online, always count on our expert’s support. Schedule a meeting with us, our colleagues will be pleased to meet you, both in-person or online.

 

Schedule a meeting button | Hovione
 





















 

Hovione offers the best chemistry, particle engineering and drug product capabilities all at the same location. With over 60 years’ experience in process development and manufacturing, we combine our innovative science, the most up-to-date technologies, and multidisciplinary teams to deliver the most impeccable end-to-end solutions, enabling your projects to go to market faster.





 

Join our exclusive Learning Lab at CPhI NA

You just need 20 minutes to learn more about the new platform for quick and effective formulation screening for Amorphous Solid Dispersions by Spray Drying. Learn more here.









 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026